The purpose of this study was to evaluate the combination of SGLT2i (sodium-glucose cotransporter 2 inhibitor) and ARNi (angiotensin receptor enkephalin inhibitor) in patients with atrial fibrillation and heart failure. The study used a randomized controlled trial design with 100 patients divided into control and experimental groups receiving conventional anti-heart failure therapy and combination therapy, respectively. The primary endpoint events included cardiovascular death, hospitalization for heart failure, and emergency department visits due to atrial fibrillation, while the secondary endpoint events included heart rate, blood pressure, improvement in cardiac function, and quality of life score. Strict quality control standards were followed during data collection, and data were collected using standardized questionnaires, physical examinations, laboratory tests, and electrocardiogram. Data were analyzed using SPSS software, including descriptive statistics, chi-square test, t-test, and the Cox regression model. The results showed that the combination group showed a trend to the control group at both primary and secondary endpoints, indicating that the combination of SGLT2i and ARNi may help to improve the treatment effect and quality of life in patients with AF and heart failure. This study provides new therapeutic strategies in the clinic and provides valuable reference information for research in related fields. However, due to the small sample size and short study duration, future larger, long-term tracked studies are still needed to further validate the effect of the combination.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: